• Overview
• Glossary
• Board of Directors
• Leadership Team
• Press Releases

Board of Directors

James (Jim) V. Mazzo is chairman and chief executive officer of Advanced Medical Optics (AMO). Mr. Mazzo has been a member of our Board of Directors since October 2001. Mr. Mazzo was President and Chief Executive Office from our inception through May 2006, at which time he also became our Chairman of the Board. Prior to AMO's spin-off from Allergan in 2002, Mr. Mazzo served in various positions at Allergan, most recently as Allergan's Corporate Vice President and President, Surgical and CLCP Businesses. From April 1998 to January 2002, Mr. Mazzo was Allergan's Corporate Vice President and President, Europe/Africa/Middle East Region. From January 2001 to January 2002, Mr. Mazzo also assumed the duties of President of Allergan's Global Surgical Business, and from May 1998 to January 2001, he was the President of Global Lens Care Products for Allergan. From June 1997 to May 1998, he was Senior Vice President, U.S. Eyecare/Rx Sales and Marketing, and prior to that he served 11 years in a variety of positions at Allergan, including Director, Marketing (Canada), Vice President and Managing Director (Italy) and Senior Vice President, Northern Europe. Mr. Mazzo first joined Allergan in 1980. Mr. Mazzo sits on the Boards of Directors of Beckman Coulter and AdvaMed (Advanced Medical Technology Association).

Christopher G. Chavez became President of St. Jude Medical's Neuromodulation business following the acquisition of Advanced Neuromodulation Systems (ANS), Inc. in November 2005. Mr. Chavez joined ANS as President, Chief Executive Officer, and Director in April 1998. Mr. Chavez has served with several Fortune 500 companies in the medical device industry, including Johnson & Johnson Medical, Inc., a major division of Johnson & Johnson (J&J). There he progressed through several positions in finance, strategic planning, domestic and international marketing, new business development, and general management to the position of Vice President & General Manager of the Infection Prevention Business Unit, one of four worldwide business units with approximately half a billion dollars in sales. Prior to joining J&J, Mr. Chavez was Vice President of Worldwide Marketing and Strategic Planning for Eastman Kodak's Health Imaging Division, where the division's five worldwide profit centers reported to him. Mr. Chavez received his MBA from the Harvard Graduate School of Business in 1979. He currently serves as a member of the board of directors for Advanced Medical Optics, Inc. and the Medical Device Manufacturers Association (MDMA).

Elizabeth (Liz) H. Dávila joined AMO's board of directors in May of 2005. Ms. Dávila is a retired executive and the former Chairman of the Board of Directors and Chief Executive Officer of VISX, Incorporated, which Advanced Medical Optics acquired in May 2005. Ms. Dávila served on the VISX Board of Directors from 1995 to 2005, and served as its Chairman and Chief Executive Officer from 2001 to 2005. From 1995 to 2001, Ms. Dávila held a number of positions at VISX, including Executive Vice President, President, and Chief Operating Officer. Prior to joining VISX, Ms. Dávila was at Syntex Corporation from 1977 to 1994, where she held senior management positions in its medical device, medical diagnostics, and pharmaceutical divisions. Ms. Dávila serves on the Board of Directors of Cholestech Corporation. She holds a masters degree in Chemistry from the University of Notre Dame and an M.B.A. from Stanford University.

Daniel J. Heinrich has been the senior vice president, chief financial officer of Clorox Co. since July 2004. He joined the Clorox Co. in March 2001 as vice president, controller. Mr. Heinrich was elected vice president, chief financial officer in October 2003. From October 1996 through February 2001, he was employed by Transamerica Finance Corporation, most recently as senior vice president, treasurer, Transamerica Finance Corporation. Prior to that, Mr. Heinrich was employed by Granite Management Corporation, an indirect subsidiary of Ford Motor Company, as senior vice president, treasurer and controller.

William J. Link, Ph.D., who joined our board of directors in June 2002, is managing director and a co-founder of Versant Ventures, a venture capital firm located in Newport Beach, California investing in early-stage health care companies. Prior to co-founding Versant Ventures in 1999, Dr. Link was a general partner at Brentwood Venture Capital, where he invested in a number of early-stage companies. From 1986 to 1997, Dr. Link was Chairman and Chief Executive Officer of Chiron Vision, a subsidiary of Chiron Corporation founded by Dr. Link, which specialized in ophthalmic surgical products and which was later sold to Bausch and Lomb in 1997. Prior to Chiron Vision, Dr. Link founded and served as President of American Medical Optics, a division of American Hospital Supply Corporation, which was sold to Allergan in 1986. Before entering the health care industry, Dr. Link was an assistant professor in the Department of Surgery at the Indiana University School of Medicine. Dr. Link earned his bachelor's, master's and doctorate degrees in mechanical engineering from Purdue University.

G. Mason Morfit, CFA, is a partner of ValueAct Capital. Prior to joining ValueAct Capital in January 2001, Mr. Morfit worked in equity research for Credit Suisse First Boston for more than two years where he supported the senior healthcare services analyst, covering 15 companies in the managed care and physician services industries. Mr. Morfit is also a director of Valeant Pharaceuticals, International, MSD Performance, Inc., and a former director of Solexa, Inc. He has a Bachelor's degree from Princeton University and is a CFA charterholder.

Michael A. Mussallem, who joined our board of directors in June 2002, is the chairman of the board and CEO of Edwards Lifesciences Corporation, a position he has held since 2000, when Edwards Lifesciences was spun off from Baxter International, Inc. Edwards Lifesciences is a medical device company focused on cardiovascular disease treatments. Mr. Mussallem joined Baxter in 1979 and was the Group Vice President of Baxter's CardioVascular business from 1994 to 2000 and Group Vice President of Baxter's Biopharmaceutical business from 1998 to 2000. In addition to serving on the Board of Edwards Lifesciences, Mr. Mussallem serves on the Boards of AdvaMed and the California Healthcare Institute.

Deborah J. Neff is the President and Chief Executive Officer of Pathwork Diagnostics, Inc. (formerly Predicant Biosciences, Inc. and Biospect, Inc.), which she joined in 2003. Pathwork is focused on applying genomics to unmet clinical needs in oncology. Prior to joining Pathwork, from 1988 to 2003, Ms. Neff held a number of executive positions at Becton Dickinson and Company, a $4 billion global medical technology and device company. Most recently, from 2000 to 2003, she was Worldwide President of Becton Dickinson Biosciences, and from 1995 to 2000, she was President of the Biosciences and Microbiology Systems as well as the Becton Dickinson Immunocytometry Systems. Before joining Becton Dickinson, Ms. Neff held senior management positions with Organon-Teknicka Corporation and CooperBiomedical. In addition to serving on the Board of Predicant, Ms. Neff is a member of the Advisory Board of the Healthcare Businesswomen's Association, and a member of the Board of Directors of ForteBio, a private life science company. Ms. Neff joined our board of directors in July 2003.

Robert (Bob) J. Palmisano joined AMO's board of directors in May of 2007. Mr. Palmisano is a retired executive and the former President, Chief Executive Officer and a director of IntraLase Corp., which Advanced Medical Optics acquired in April 2007. Mr. Palmisano joined IntraLase Corp. as President, Chief Executive Officer and a director in April 2003. From April 2001 to April 2003, Mr. Palmisano was the president, chief executive officer and a director of MacroChem Corporation, a development stage pharmaceutical corporation. From April 1997 to January 2001, Mr. Palmisano served as president and chief executive officer and a director of Summit Autonomous, Inc., a global medical products company that was acquired by Alcon, Inc. in October 2000. Prior to 1997, Mr. Palmisano held various executive positions with Bausch & Lomb Incorporated, a global eye care company. Mr. Palmisano earned his bachelor's degree in political science from Providence College.

James O. Rollans joined our board of directors in June 2002 and serves as presiding director. Mr. Rollans retired in 2003 from the Board of Directors of Fluor Corporation and from his position as Fluor's Group Executive of Investor Relations and Corporate Communications, in which he was responsible for leading the company's external affairs, including Investor Relations, Corporate Communications, Community and Government Relations functions. Prior to assuming that role in February 2002, Mr. Rollans served as Group Executive of Business Services (from February 2001). Joining Fluor in 1982, Mr. Rollans' tenure with the company included several positions at the senior executive level, including that of Senior Vice President and Chief Administrative Officer from 1994 to 1998; Senior Vice President and Chief Financial Officer from 1998 to 1999 and from 1992 to 1994; and Vice President of Corporate Communications from 1982 to 1992. He also served as the first President and Chief Executive Officer of Fluor Signature Services, the former business services enterprise of Fluor Corporation from 1999 to 2001. Fluor is an engineering, procurement, construction and maintenance services company. Mr. Rollans is a member of the Board of Directors of Flowserve Corporation and Encore Credit Corporation.